Ozempic得到欧盟批准更新其标签,以包括降低肾病风险。 Ozempic gets EU approval to update its label to include reducing kidney disease risks.

欧洲监管机构认可诺沃·诺迪斯克的Ozempic将其减少肾病风险的能力列入其标签。 The European regulatory body has endorsed Novo Nordisk's Ozempic for inclusion of its ability to reduce risks associated with kidney disease on its label. 这一更新反映了在减少肾病相关事件、加强药物的核定用途方面的积极成果。 This update reflects positive outcomes in reducing events related to kidney disease, enhancing the medication's approved uses.